This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barratt-Boyes, S. M. Articles by Finn, O. J. Search for Related Content PubMed PubMed Citation Articles by Barratt-Boyes, S. M. Articles by Finn, O. J.

Immunization of Chimpanzees with Tumor Antigen MUC1 Mucin Tandem Repeat Peptide Elicits Both Helper and CytotoxicT-Cell Responses¹

Departments of Infectious Diseases and Microbiology [S. M. B-B.] and Molecular Genetics and Biochemistry [A. V., O. J. F.], University of Pittsburgh, Pittsburgh, Pennsylvania 15261; and Yerkes Regional Primate Research Center, Emory University, Atlanta, Georgia 30322 [O. J. F.]

CTLs and antibody responses to the tumor-associated antigen MUC1 mucin can be detected in patients with adenocarcinomas of the breast, pancreas, colon, and ovary. However, neither response is generally effective at controlling disease. Methods to augment immunity to MUC1 are being designed, with the expectation that this will lead to an antitumor response. The key to eliciting potent immunity to tumor MUC1 may be in generating MUC1-specific T-helper cell responses, which, to date, have not been reported in cancer patients. We have recently demonstrated that a synthetic vaccine representing five copies of the MUC1 tandem repeat peptide can be used to prime MUC1-specific human CD4⁺ T cells in vitro. Here, we extend these studies to test the immunogenicity and safety of the tandem repeat peptide in the chimpanzee, which has the identical MUC1 tandem repeat sequence to the human. To promote induction of Th1-type responses, we used the novel adjuvant LeIF, a Leishmania-derived protein that is known to stimulate human peripheral blood mononuclear cells (PBMCs) and antigen-presenting cells, to produce a Th1-type cytokine profile. We found that MUC1 tandem repeat peptide administered with LeIF elicited positive, albeit transient, proliferative T-cell responses to MUC1 in the PBMCs from four of four chimpanzees. Immunization induced MUC1-specific IFN- but not interleukin 4 expression in CD4⁺ T cells from PBMCs and draining lymph nodes. MUC1-specific CTLs were also generated that did not induce detectable autoimmune dysfunction during the 1 year of observation. We conclude that the MUC1 tandem repeat peptide can be used to elicit both T-helper and cytotoxic cell responses to MUC1 in the primate and holds promise as a safe and effective cancer vaccine.

This article has been cited by other articles:

				W. Guojun, G. Wei, O. Kedong, H. Yi, X. Yanfei, C. Qingmei, Z. Yankai, W. Jie, F. Hao, L. Taiming, et al. A novel vaccine targeting gastrin-releasing peptide: efficient inhibition of breast cancer growth in vivo Endocr. Relat. Cancer, March 1, 2008; 15(1): 149 - 159. [Abstract] [Full Text] [PDF]

				L. Zhang, Y. Tang, H. Akbulut, D. Zelterman, P.-J. Linton, and A. B. Deisseroth An adenoviral vector cancer vaccine that delivers a tumor-associated antigen/CD40-ligand fusion protein to dendritic cells PNAS, December 9, 2003; 100(25): 15101 - 15106. [Abstract] [Full Text] [PDF]

				M. M. Soares, V. Mehta, and O. J. Finn Three Different Vaccines Based on the 140-Amino Acid MUC1 Peptide with Seven Tandemly Repeated Tumor-Specific Epitopes Elicit Distinct Immune Effector Mechanisms in Wild-Type Versus MUC1-Transgenic Mice with Different Potential for Tumor Rejection J. Immunol., June 1, 2001; 166(11): 6555 - 6563. [Abstract] [Full Text] [PDF]

				E. M. Hiltbold, A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn The Mechanism of Unresponsiveness to Circulating Tumor Antigen MUC1 Is a Block in Intracellular Sorting and Processing by Dendritic Cells J. Immunol., October 1, 2000; 165(7): 3730 - 3741. [Abstract] [Full Text] [PDF]

				U. Manne, H. L. Weiss, and W. E. Grizzle Racial Differences in the Prognostic Usefulness of MUC1 and MUC2 in Colorectal Adenocarcinomas Clin. Cancer Res., October 1, 2000; 6(10): 4017 - 4025. [Abstract] [Full Text]